Inter Partes Review Proceedings
PTAB Portal
IPR Case No(s):
U.S. Patent No.
8,802,100 (Formulation of Human Antibodies for Treating TNF-Alpha Associated Disorders)
Patent Owner
AbbVie Biotechnology Ltd.
Petitioner(s)
Sandoz Inc.
§ 102 Challenge
N
§ 103 challenge
Y
Claim Types Challenged Under § 103
Formulation
§ 103 Challenge Instituted
N
IPR Status
IPR Not Instituted
U.S. Patent No.
9,512,216 (Use of TNF-Alpha Inhibitor)
Patent Owner
AbbVie Biotechnology Ltd.
Petitioner(s)
Sandoz Inc.
§ 102 Challenge
N
§ 103 challenge
Y
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
N
Federal Circuit Appeal(s)
18-2142
IPR Status
IPR Not Instituted; Request for Rehearing Denied; Federal Circuit Appeal Voluntarily Dismissed
U.S. Patent No.
8,911,737 (Methods of Administering Anti-TNF Alpha Antibodies)
Patent Owner
AbbVie Biotechnology Ltd.; Abbott Biotechnology Ltd.
Petitioner(s)
Sandoz Inc.
§ 102 Challenge
N
§ 103 challenge
Y
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
N
Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Settled while Request for Rehearing of Decision Denying Institution was Pending)
IPR Status
IPR Not Instituted; Request for Rehearing Terminated Due to Settlement
U.S. Patent No.
8,974,790 (Methods of Administering Anti-TNF Alpha Antibodies)
Patent Owner
AbbVie Biotechnology Ltd.; Abbott Biotechnology Ltd.
Petitioner(s)
Sandoz Inc.
§ 102 Challenge
N
§ 103 challenge
Y
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
N
Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Settled while Request for Rehearing of Decision Denying Institution was Pending)
IPR Status
IPR Not Instituted; Request for Rehearing Terminated Due to Settlement
U.S. Patent No.
9,090,689 (Use of TNF-Alpha Inhibitor for Treatment of Psoriasis)
Patent Owner
AbbVie Biotechnology Ltd.
Petitioner(s)
Sandoz Inc.
§ 102 Challenge
N
§ 103 challenge
Y
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y
Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Settled After Institution)
IPR Status
Terminated Due to Settlement After Institution
U.S. Patent No.
9,067,992 (Use of TNF-Alpha Inhibitor for Treatment of Psoriatic Arthritis)
Patent Owner
AbbVie Biotechnology Ltd.
Petitioner(s)
Sandoz Inc.
§ 102 Challenge
Y
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Y
§ 103 challenge
Y
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y
Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Settled After Institution)
IPR Status
Terminated Due to Settlement After Institution
U.S. Patent No.
9,512,216 (Use of TNF-Alpha Inhibitor)
Patent Owner
AbbVie Biotechnology Ltd.
Petitioner(s)
Sandoz Inc.
§ 102 Challenge
N
§ 103 challenge
Y
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
N
Federal Circuit Appeal(s)
18-2143 (Consolidated with lead appeal 18-2142)
IPR Status
IPR Not Instituted; Federal Circuit Appeal Voluntarily Dismissed
U.S. Patent No.
9,187,559 (Multiple-Variable Dose Regimen for Treating Idiopathic Inflammatory Bowel Disease)
Patent Owner
AbbVie Biotechnology Ltd.
Petitioner(s)
Sandoz Inc.
§ 102 Challenge
N
§ 103 challenge
Y
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
N
IPR Status
IPR Not Instituted